(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/090300 A1

(51) International Patent Classification[7]: C07D 207/26, 401/04, 401/10, 405/10, 211/76, 405/04, 413/10, 403/10, 405/14, A61K 31/4015, 31/4025, 31/45, 31/4523, A61P 25/00

(21) International Application Number:
PCT/IB2005/000583

(22) International Filing Date: 7 March 2005 (07.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/553,808 17 March 2004 (17.03.2004) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BRODNEY, Michael, Aaron** [US/US]; Eastern Point Road, Groton, CT 06340-5146 (US). **CARON, Stephane** [CA/US]; Eastern Point Road, Groton, CT 06340-5146 (US). **HELAL, Christopher, J.** [US/US]; Eastern Point Road, Groton, CT 06340-5146 (US). **RAGGON, Jeffrey, W.** [US/US]; Eastern Point Road, Groton, CT 06340-5146 (US). **TAO, Yong** [CA/US]; Eastern Point Road, Groton, CT 06340-5146 (US). **DO, Nga, M.** [US/US]; Eastern Point Road, Groton, CT 06340-5146 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., P.O. Box 1027, St. Louis, MO 63006 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES



(I)



G1



G2

(57) Abstract: The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula (I) wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13, X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.

WO 2005/090300 A1